/
Not financial advice. Analytical data for research only.
Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.
Pharmaceutical preparations company · B9 · FY ends Dec · Revenue $361M · -139.89% margin · -$153M FCF
$0.11
+$0.00 (+0.00%)
EOD Sep 1, 2026
The business is unprofitable at the operating level (-139.89% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue declined 23.1% YoY. The question is whether this is cyclical or a structural shift.
Negative free cash flow of -$153M. The business is consuming cash, not generating it.
0.1x earnings. The multiple is below average. Either the market is pricing in deterioration you should investigate, or there's genuine value here.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$361M
▼ -23.1% YoY
Net Income (TTM)
$91M
▲ +773.8% YoY
Op. Margin
-139.89%
▲ +12.0pp YoY
ROIC
-4.52%
▲ +1.7pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$153M
▼ -772.4% YoY
Op. Cash Flow (TTM)
-$57M
▼ -141.0% YoY
Net Debt
-$9.56B
Net Cash Position
Cash & Equiv.
$9.95B
5Y CAGR: +8.0%
Continue Research
SourceComputed from the 10-K filed 30 Apr 2026, covering the period ending 31 Dec 2024, as reported to the SEC. Data last refreshed 30 Apr 2026. How this is calculated.
Price from market data, last close as of 1 Sept 2026. Fiscal year ends Dec. Sector medians are approximate S&P 500 benchmarks and update periodically.
At a P/E of 0.1, A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in .
On quality, Sinovac Biotech scores 30/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. It currently yields about 11,980.2%; see dividend safety for coverage and history. All figures are computed from SEC filings; read the full methodology. This is analysis, not investment advice.
Sinovac Biotech scores 30 out of 100 on Intrinsiqq's quality score, a weighted blend of 7 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -139.9% operating margin and a -4.5% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
Yes, Sinovac Biotech pays a regular dividend of about $13.18 per share per year (typically in quarterly installments), a yield of roughly 11,980.2% at the current price. That is a payout ratio of about 1,041.7% of earnings, so the dividend is stretched at this level. A low headline yield is not the same as a weak dividend: what matters is how well earnings and free cash flow cover the payout and whether it is growing, not the percentage alone. For SVA's full payout history, growth streak and dividend-safety score, see the dividends tab.
That depends on valuation and quality together, not either alone. you should weigh SVA's valuation and scores 30/100 on quality (lower-quality). It also yields about 11,980.2%. A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.